Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 23, 2015. The report serves as a notification of a specific corporate governance change rather than a financial results announcement.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to a directorate change announcement and contains no financial performance data.
Material Changes
The primary material change disclosed is the appointment of Dr. Jesse Goodman to the Board of Directors as a Non-Executive Director and Scientific and Medical Expert, effective January 1, 2016.
Management Commentary and Governance Details
- Appointment Rationale: Chairman Philip Hampton stated that Dr. Goodman brings expertise in science, medicine, vaccines, regulation, and public health, with a proven record in addressing public health needs from both academic and federal sectors.
- Background: Dr. Goodman is currently a Professor of Medicine at Georgetown University and previously served as the FDA's chief scientist and Director of the Center for Biologics Evaluation and Research (CBER).
- Compensation: Dr. Goodman will receive standard annual fees of £85,000 plus an additional £30,000 for his role as Scientific and Medical Expert. At least 25% of these fees will be converted into GSK ADSs.
- Independence: The Board has determined Dr. Goodman is an independent Non-Executive Director in accordance with the UK Corporate Governance Code.
- Updated Board Composition: The filing lists the full Board composition effective January 1, 2016, including Sir Philip Hampton (Chairman), Sir Andrew Witty (CEO), and Simon Dingemans (CFO).
Key Facts for Investor Verification
- Verify the effective date of Dr. Goodman's appointment (January 1, 2016).
- Confirm the total annual compensation package (£115,000) and the share conversion requirement (25% into ADSs).
- Note that this filing contains no financial results; investors should refer to the Annual Report on Form 20-F for financial data.
- Review the updated Board of Directors list to confirm the new composition.